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Abstract
Background: We compared microRNA expression patterns in three cisplatin resistant sublines derived from
paternal cisplatin sensitive germ cell tumor cell lines in order to improve our understanding of the mechanisms of
cisplatin resistance.
Methods: Three cisplatin resistant sublines (NTERA-2-R, NCCIT-R, 2102EP-R) showing 2.7-11.3-fold increase in drug
resistance after intermittent exposure to increasing doses of cisplatin were compared to their parental counterparts,
three well established relatively cisplatin sensitive germ cell tumor cell lines (NTERA-2, NCCIT, 2102EP). Cells were
cultured and total RNA was isolated from all 6 cell lines in three independent experiments. RNA was converted
into cDNA and quantitative RT-PCR was run using 384 well low density arrays covering almost all (738) known
microRNA species of human origin.
Results: Altogether 72 of 738 (9.8%) microRNAs appeared differentially expressed between sensitive and resistant
cell line pairs (NTERA-2R/NTERA-2 = 43, NCCIT-R/NCCIT = 53, 2102EP-R/2102EP = 15) of which 46.7-95.3% were up-
regulated (NTERA-2R/NTERA-2 = 95.3%, NCCIT-R/NCCIT = 62.3%, 2102EP-R/2102EP = 46.7%). The number of genes
showing differential expression in more than one of the cell line pairs was 34 between NTERA-2R/NTERA-2 (79%)
and NCCIT-R/NCCIT (64%), and 3 and 4, respectively, between these two cell lines and 2102EP-R/2102EP (about
27%). Only the has-miR-10b involved in breast cancer invasion and metastasis and has-miR-512-3p appeared to be
up-regulated (2-3-fold) in all three cell lines. The hsa-miR-371-373 cluster (counteracting cellular senescence and
linked with differentiation potency), as well as hsa-miR-520c/-520h (inhibiting the tumor suppressor p21) were
3.9-16.3 fold up-regulated in two of the three cisplatin resistant cell lines. Several new micro-RNA species missing
an annotation towards cisplatin resistance could be identified. These were hsa-miR-512-3p/-515/-517/-518/-525
(up to 8.1-fold up-regulated) and hsa-miR-99a/-100/-145 (up to 10-fold down-regulated).
Conclusion: Examining almost all known human micro-RNA species confirmed the miR-371-373 cluster as a
promising target for explaining cisplatin resistance, potentially by counteracting wild-type P53 induced senescence
or linking it with the potency to differentiate. Moreover, we describe for the first time an association of the up-
regulation of micro-RNA species such as hsa-miR-512-3p/-515/-517/-518/-525 and down-regulation of hsa-miR-99a/-
100/-145 with a cisplatin resistant phenotype in human germ cell tumors. Further functional analyses are warranted
to gain insight into their role in drug resistance.
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Cisplatin (cis-diamminedichloroplatinum II, CDDP) is a
chemotherapeutic agent widely used in the treatment of
several solid tumors, among them testicular cancer, lung
cancer, breast cancer, and bladder cancer. Resistance to
cisplatin is a serious obstacle to effective cancer therapy.
Clinically relevant levels of resistance can emerge
quickly after treatment. Beside intrinsic resistance,
acquired or gradually developing resistance has been
observed in tumors under therapy. Several mechanisms
underlying resistance have been described, like
decreased exposure to the drug, e.g. via reduced drug
accumulation/drug-target interaction or increased detox-
ification response, diminished cell-cycle effects, reduced
apoptotic responses, or increased DNA-repair [1,2]. A
number of these biological processes are controlled on a
post-transcriptional level by noncoding micro-RNA spe-
cies. We created an in vitro model of acquired cisplatin
resistance by long term exposure of three well estab-
lished germ cell tumor cell lines to cisplatin, resulting in
sublines with significantly increased resistance to cispla-
tin. The paternal cell lines are (1) the p53-wt (wild type)
pluripotent gonadal germ cell tumor cell line NTERA-2,
(2) the p53-mutated pluripotent extragonadal nonsemi-
nomatous germ cell tumor cell line NCCIT and (3) the
p53-wt nullipotent embryonal cell carcinoma 2102EP,
derived from a primary human testicular teratocarci-
noma. NCCIT cells have previously been shown to have
an approximately 4-fold higher IC50 to cisplatin, com-
pared to NTERA-2 [3]. We utilized a quantitative RT-
PCR (RTQ-PCR) based platform for detection of almost
all currently known (738) human micro-RNA species on
these 6 cell lines. Our approach was designed to charac-
terize the role of micro-RNAs on the presumably multi-
factorial phenomenon of acquired cisplatin resistance in
germ cell tumors.
Methods
1 Cell lines
Both chemo sensitive paternal 2102EP (PW Andrews,
Sheffield, U.K.) and NCCIT (ATCC, Manassas, VA,
USA) cells as well as their cisplatin resistant sublines
were cultured in DMEM F12 (1:1) medium containing
10% fetal calf serum (Gibco-BRL, Invitrogen, U.K.).
NTERA-2 (DSMZ, Braunschweig, Germany) and the cis-
platin resistant subline were cultured in DMEM medium
supplemented with Glutamax-I (Gibco-BRL, Invitrogen,
U.K.) containing 10% fetal calf serum (Gibco-BRL, Invi-
trogen, U.K.). Cells were incubated at 37°C in a humidi-
fied atmosphere with 5% CO2 and were passaged every
3-4 days. After trypsination of cultured cells from steady
state conditions and at comparable cell density, aliquots
containing 10 × 10
6 cells were transferred into 1 ml
RNA-later solution and stored at -20°C. Three aliquots
per cell line originating from different cell passages
(n+2, n+4 and n+5) were processed and stored as
described above.
2 Induction of cisplatin resistance
The cisplatin resistant sublines NTERA-2-R, 2102EP-R
and NCCIT-R were generated by intermittent exposure
of the parental cell lines to cisplatin over a time period
of 18 month, starting with the respective IC10 dose of
each parental cell line. At reaching 50% cell kill, the
addition of cisplatin was interrupted and cells were
allowed to recover over three passages. Analyses pre-
sented here were performed after maintaining the resis-
tant sublines for at least 1 week in cisplatin-free
medium to allow for an adequate wash-out period.
Results of cytotoxicity experiments of all six cell lines
using the MTT assay (3-(4,5-Dimethylthiazol-2-Yl)-2,5-
Diphenyltetrazolium Bromide) have been published [4]
The experiments were performed in 3 completely inde-
pendent replicates for every cell line including genera-
tion of resistant cell lines, cell culture, RNA isolation
and RTQ-PCR measurements.
3 RNA Isolation
Cells were transported on dry ice in RNA-later solution
(Qiagen, Hilden, Germany) and stored at -80°C until
use. After thawing the cells, they were disrupted using a
denaturing lysis buffer, and RNA was isolated by com-
bining organic extraction (phenol-chloroform) followed
by immobilization of RNA on glass-fiber filters employ-
ing the mirVana miRNA Isolation Kit (Ambion, Applied
Biosystem, Weiterstadt, Germany) in order to purify
total RNA including small RNA species. Remaining
DNA was digested on glass-fiber filters (RNase free
DNase Set,Qiagen, Hilden, Germany), and after per-
forming quality controls, RNA was stored at -80°C until
analysis by RTQ-PCR.
To control the quality and purity (protein or DNA
contamination) of isolated total RNA including small
RNA, we performed spectral photometry, agarose gel
electrophoresis, and PCR (using b-Actin primers). Only
high quality total RNA including small RNA species was
used for further experiments.
4 RTQ-PCR with “Low Density Array” (LDA)
Aliquots from each RNA sample (10 × 1 μg) were rever-
sely transcribed without preamplification over three
hours using the so called “Megaplex pools without pre-
amplification protocol for microRNA expression analysis
protocol”. In a second step, the whole template cDNA
and 450 μl 2x RT-PCR master mix were adjusted to a
total volume of 900 μlb ya d d i n gn u c l e a s ef r e ew a t e r ,
and aliquots of 100 μl were pipetted into each fill port
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Page 2 of 8(12,000 rpm, 1 min, Multifuge3S-R, Heraeus, Germany),
sealed, transferred into the 7900 RTQ-PCR instrument
and a specific RTQ-PCR protocol was run over two
hours using the 384-well LDA format. Two different
LDAs existed, thus covering 738 human micro-RNAs.
This made it necessary to create two kinds of cDNAs
suitable for each of both LDAs using different sets of
primers.
Normalization was performed using the median gene
expression on each LDA separately, because this proved
to be the more robust and slightly more precise method
compared to a normalization approach using a house-
keeping micro-RNA species provided on the LDA (data
not shown). The median gene expression was subtracted
from the CT-value of each of the spotted genes, follow-
ing the ΔCT-quantitative approach for normalization
purposes. Normalized gene expression results of cispla-
tin-resistant cell lines were expressed relative to the
genes measured in the paternal chemosensitive cell lines
by subtracting the corresponding CT-values (ΔΔCT-
quantitative approach). As a result, differential gene
expression of cisplatin-resistant cell lines was expressed
as a several-fold up- or down regulation of micro-RNAs
relative to their paternal chemo sensitive origin. These
ratios of corresponding cell line pairs are expressed such
as e.g. NTERA-2-R/NTERA-2. Only ratios ≥2/≤0.5 were
considered to represent differentially expressed genes.
All the materials and instruments used for RTQ-PCR
were ordered from Applied Biosystems, Weiterstadt,
Germany.
All technical procedures were performed in accor-
dance to standard operating procedures (SOP) imple-
mented in our laboratory in 2008 when the Institute
became accredited according to DIN EN ISO 9001/2008.
5 Statistics
Statistical measures (e.g. coefficient of variation, CV and
25-75% quantiles) were computed using SAS (release
9.1.3, Cary NC, USA).
Results
Intermittently culturing NTERA-2, 2102EP, and NCCIT
cell lines exposed to increasing concentrations of cisplatin
resulted in a 2.7 - 11.3 increase in IC50 to the substance, as
measured by the MTT assay (3-(4,5-Dimethylthiazol-2-
Yl)-2,5-Diphenyltetrazolium Bromide). Whereas the IC50
values of the sensitive parental cell lines were 0.45 μM
(+/-0.1 standard deviation, SD), 0.75 μM( + / -0 . 1 ) ,
and 1.75 μM (+/- 0.1), respectively, the three cisplatin
resistant sublines exhibited IC50 values of 5.1 μM
(+/- 0.1) in NTERA-2R, 4.9 μM (+/- 0.1) in 2102EP-
R, and 4.7 μM (+/- 0.2 ) in NCCIT-R. Results of the
cytotoxicity experiments have been reported else-
where [4].
The coefficient of variation (CV, measure of standard
deviation variability expressed in percent relative to the
mean differential gene expression for each micro-RNA)
was chosen to describe the observed methodological,
intra- and interindividual variability of our three inde-
pendently performed experiments. Mean CV values of
differentially expressed genes and associated interquar-
tile ranges appeared cell line dependent, showing
increased mean CV values (25-75 percentile) starting at
25.3% (25-75 percentile: 15.7-29.0) in cell line pairs such
as NCCIT-R/NCCIT, 30.5% (25-75 percentile: 18.5-36.3)
in NTERA-2-R/NTERA-2, and 37.4% (25-75 percentile:
18.6-40.4) in 2102EP-R/2102EP cells (table 1). On aver-
age, mean CV did not exceed 30% (28.9%).
About 30-45% of the 738 microRNAs examined
showed CT-values within the linear dynamic range of
the method (CT 7-29, data not shown). Altogether 72 of
738 genes appeared differentially expressed (table 2)
with 43, 53 and 15 genes found in NTERA-2-R/
NTERA-2, NCCIT-R/NCCIT and 2102EP-R/2102EP cell
line pairs, respectively (figure 1). On average 72% of the
genes were up-regulated in resistant compared to sensi-
tive cells, a feature that was more prominent in
NTERA-2-R/NTERA-2 (41 of 43 genes, 95.3%) com-
pared to NCCIT-R/NCCIT (33 of 53 genes, 62.3%) or
even 2102EP-R/2102EP (7 of 15 genes, 46.7%) cell pairs
(table 2). The number of down-regulated genes ranged
f r o m4 . 7 %i nN T E R A - 2 - R / N T E R A - 2( 2o f4 3g e n e s )t o
37.7% in NCCIT-R/NCCIT (20 of 53 genes) and 53.3%
in 2102EP-R/2102EP cell line pairs (8 of 15 genes).
Thirty-four overlapping genes were found in the two
pairs NTERA-2-R/NTERA-2 ( 3 4o f4 3g e n e s ,7 9 % )a n d
NCCIT-R/NCCIT (34 of 53 genes, 64%). The overlap-
ping number of differentially expressed genes was only 5
between cell line pairs NTERA-2-R/NTERA-2 and
2102EP-R/2102EP, and 6 between NCCIT-R/NCCIT
and 2102EP-R/2102EP (about 27%). Only hsa-miR-10b
Table 1 Differential gene expression relative to the
corresponding gene of the paternal cell line
Cell lines
CV
distribution
NTERA-2-R/
NTERA-2
NCCIT-R/
NCCIT
2102EP-R/
2102EP
together
mean 30.5 25.3 37.4 28.9
median 27.3 21.7 32.7 24.1
25-75
percentile
18.5-36.3 15.7-29.0 18.6-40.4 16.5-33.8
n 43 53 15 111
The coefficient of variation (CV, chosen as a measure of standard deviation
variability expressed in percent relative to the mean differential gene
expression) was calculated for each micro-RNA species. Parameters of CV
distribution such as mean, median and first-third quartile range were
calculated and depicted for each cell line pair consisting of the cisplatin-
resistant (-R added to the paternal cell line’s name) relative to the cisplatin-
sensitive paternal cell line as well as summarized.
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Page 3 of 8Table 2 Differential gene expression relative to the corresponding gene of the paternal cell line.
Mean differential gene expression in cell line pairs Mean differential gene expression in cell line pairs
NTERA-2-R/NTERA-2 NCCIT-R/NCCIT 2102EP-R/2102EP NTERA-2-R/NTERA-2 NCCIT-R/NCCIT 2102EP-R/2102EP
Detector fold-
change
SEM p-
value
fold-
change
SEM p-
value
fold-
change
SEM p-
value
Detector fold-
change
SEM p-
value
fold-
change
SEM p-
value
fold-
change
SEM p-
value
hsa-miR-708 0.5 0.1 0.014 0.4 0.1 0.004 hsa-miR-525-
3p
6.8 1.3 0.009 8.0 0.9 <0.001
hsa-miR-130b 0.5 0.1 0.096 hsa-miR-519a 6.8 1.0 0.008 6.0 0.9 0.081*
hsa-miR-455-
5p
2.0 0.4 0.059 hsa-miR-518a-
3p
6.9 1.1 0.004 7.2 0.3 <0.001
hsa-miR-193b 2.1 0.5 0.036 hsa-miR-520b 7.0 2.3 0.004 5.5 0.8 <0.001
hsa-miR-146a 2.1 0.3 0.1* 2.6 0.1 <0.001 hsa-miR-517b 7.2 1.2 0.003 6.4 1.5 0.006
RNU43 2.2 0.3 0.1* hsa-miR-518b 7.3 0.4 <0.001 8.1 1.2 <0.001
hsa-miR-526b 2.2 0.4 0.061 hsa-miR-515-
5p
7.8 1.0 0.005 5.6 0.3 <0.001
hsa-miR-302b 2.3 1.2 0.512 0.5 0.1 0.058 hsa-miR-145 0.0 0.0 <0.001
hsa-miR-524-
3p
2.4 0.1 0.019 hsa-miR-100 0.1 0.0 <0.001
hsa-miR-10b 2.8 0.6 0.006 2.0 0.6 0.081* 2.7 0.5 0.126 hsa-miR-99a 0.1 0.0 <0.001
hsa-miR-205 2.9 0.5 0.004 0.5 0.1 0.034 hsa-miR-582-
5p
0.2 0.0 <0.001
hsa-miR-518c 2.9 0.4 0.004 hsa-miR-125b 0.2 0.0 <0.001 0.4 0.0 0.012
hsa-miR-801 3.0 1.0 0.172 hsa-miR-450b-
5p
0.4 0.0 0.038
hsa-miR-523 3.5 0.1 0.004 3.0 0.5 0.012 hsa-miR-302d 0.4 0.0 <0.001
hsa-miR-362-
3p
3.7 1.7 0.026 2.4 0.8 0.132 hsa-miR-192 0.4 0.1 0.004
hsa-miR-520f 3.7 0.3 0.010 2.4 0.3 0.001 hsa-miR-218 0.5 0.1 0.030 0.3 0.0 <0.001
hsa-miR-520h 3.9 0.4 <0.001 7.1 0.7 <0.001 hsa-miR-335 0.5 0.1 0.062
hsa-miR-371-
3p
4.0 0.3 <0.001 15.2 2.1 <0.001 hsa-miR-21 0.5 0.0 0.061
hsa-miR-373 4.1 0.7 0.006 12.0 2.9 <0.001 hsa-miR-576-
3p
0.5 0.1 0.001
hsa-miR-519c-
3p
4.3 0.3 0.008 3.2 0.3 0.001 hsa-miR-363 0.5 0.0 0.001
hsa-miR-522 4.3 0.7 0.002 6.4 0.4 0.002 hsa-miR-424 0.5 0.0 0.002
hsa-miR-526b 4.3 0.5 <0.001 8.3 2.3 0.002 hsa-miR-302a 0.5 0.0 0.003
hsa-miR-519b-
3p
4.4 0.4 0.006 7.8 1.0 0.003 hsa-miR-194 0.5 0.2 0.078
hsa-miR-518d-
5p
4.5 0.5 0.004 3.3 0.4 0.001 hsa-miR-221 0.5 0.1 0.034
hsa-miR-516b 4.5 0.4 0.002 3.1 0.5 0.002 hsa-miR-935 2.5 0.1 <0.001
hsa-miR-512-
5p
4.6 1.3 0.021 6.3 0.8 0.001 hsa-miR-383 13.3 2.8 <0.001
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8Table 2 Differential gene expression relative to the corresponding gene of the paternal cell line. (Continued)
hsa-miR-520c-
3p
4.6 0.6 <0.001 5.6 0.5 0.002 hsa-miR-489 0.1 0.0 <0.001
hsa-miR-372 4.7 1.0 0.081* 16.3 2.0 <0.001 hsa-miR-365 0.3 0.1 <0.001
hsa-miR-512-
3p
5.1 0.9 0.004 7.8 1.2 <0.001 2.1 0.2 0.024 hsa-miR-193a-
5p
0.4 0.1 0.008
hsa-miR-518f 5.2 0.7 0.003 6.3 0.9 <0.001 hsa-miR-296-
5p
0.4 0.0 0.003
hsa-miR-519d 5.2 0.7 0.001 7.0 2.6 0.003 hsa-miR-484 0.4 0.0 0.002
hsa-miR-517a 5.3 1.2 0.005 6.0 0.6 <0.001 hsa-miR-335* 0.5 0.0 0.007
hsa-miR-520g 5.8 0.6 0.005 7.5 1.5 <0.001 hsa-miR-34a 2.4 0.4 0.048
hsa-miR-517c 6.1 0.5 0.001 6.7 0.5 <0.001 hsa-miR-923 2.4 0.6 0.188*
hsa-miR-515-
3p
6.4 0.2 <0.001 4.8 0.5 <0.001 hsa-miR-146b-
5p
3.9 0.6 0.081
hsa-miR-518e 6.7 0.4 0.001 8.1 1.5 <0.001 hsa-miR-19b-1 5.7 3.5 0.081
Differential gene expression (mean fold-change from three independent experiments) was calculated from gene expression measured in the chemoresistant cell line (-R added to the paternal cell line’s name) relative
to the corresponding gene of the paternal cell line. Genes are listed in ascending order of the NTERA-2 cell’s fold-change followed by NCCIT and 2102EP values. P-values were calculated with t-test (equal variance
and normal distributed data) and values with asterix with the MannWhitney rank sum test.
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8and has-miR-512-3p species were found to be up-regu-
lated (2-8-fold) in all three cell lines.
Taken together, NTERA-2-R/NTERA-2 and NCCIT-
R/NCCIT shared the vast majority of their differentially
altered micro-RNAs, whereas 2102EP-R/2102EP showed
a rather different profile. A complete list of all detect-
able miRNA examined is provided as additional file
(additional file 1: Table S1).
Discussion
Our approach enabled us to investigate almost all cur-
rently known human micro-RNAs simultaneously.
Quantitative RT-PCR was chosen because of it’sr e c o g -
n i z e dp r e c i s i o na n ds u p e r i o rity over other methods for
gene expression analysis [5-7]. Our experiments were
run in triplicate and on average revealed a CV <30%
covering variability caused by methodological (mean CV
<5%, data not shown), intra- and inter-individual
sources (table 1). Since this CV is clearly below the defi-
nition of a two-fold threshold for differential gene
expression, we are convinced that the results of our ana-
lysis represent true differences in micro-RNA expression
between the cell line pairs.
Of 738 micro-RNA species examined, only 9.8% (72)
appeared differentially expressed with considerable over-
lap in micro-RNA gene expression occurring between
the cell line pairs NTERA-2-R/NTERA-2 and NCCIT-R/
NCCIT, but considerably less overlap with the cell line
pair 2102EP-R/2102EP cells (table 1).
Functionally, the most striking distinguishing feature
between the cell lines NTERA-2 and NCCIT on the one
hand, and 2102EP on the other hand is a difference in
their capacity to differentiate. Whereas the former two
lines can differentiate upon stimuli such as exposure to
retinoid acid, the latter is nullipotent and is therefore
devoid of alterations induced by processes of cellular
differentiation [8]. Interestingly, there is increasing evi-
dence for a link between cellular differentiation and
resistance to chemotherapy in germ cell tumors, both in
cell line models, as well as in primary tumor material,
which seems to be linked to two microRNA clusters,
namely miR371-373 and miR302 [9].
In contrast to many features shared by NTERA-2 and
NCCIT, extragonadal NCCIT cells show a higher resis-
tance level to cisplatin, compared to NTERA-2 [3]. In this
context, the several fold-change differences measured in
the micro-RNA cluster covering hsa-miR-371-373 is of
interest. Based on our findings, hsa-miR-371-373
expression in NTERA-2-R increased 4.0-4.7-fold relative
to the paternal cisplatin sensitive NTERA-2 line, and
even more in NCCIT-R, relative to the cisplatin sensi-
tive paternal NCCIT cells, showing an 12.0-16.3-fold
upregulation, table 1. Noteworthy, this micro-RNA clus-
ter has been discussed in the context of the presence of
wild-type p53 in germ cell tumors, counteracting
tumorigenesis by induction of senescence [2,10,11]. By
up-regulation, the cluster prevents p53-driven cellular
senescence via a plethora of target genes, e.g. NEO1 or
LATS2 [2], therefore leading to cell proliferation even
i nt h ep r e s e n c eo fw i l d - t y p ep 5 3 .F u r t h e r m o r e ,t h i s
cluster has been described in cells exhibiting stem cell
properties [12]. Noteworthy, this cluster has recently
been identified by other authors to be the most signifi-
cant differentially expressed microRNA in human germ
cell tumors [13]. Therefore, it appears a promising tar-
get for further analysis in germ cell tumors, e.g. by
posttranscriptional silencing with siRNA, to examine
the functional role of the cluster in altering gene
expression and thereby elucidate it’sc o n t r i b u t i o nt ot h e
development of cisplatin resistance.
As already mentioned, there are other gene changes
which have been discussed in the context of cisplatin
up-regulated
NTERA-2-R/
NTERA-2
(43)
NCCIT-R/
NCCIT
(53)
2102EP-R/
2102EP
(15)
32
4 3
2
NTERA-2-R/
NTERA-2
(2)
NCCIT-R/
NCCIT
(20)
2102EP-R/
2102EP
(8)
1
2
0
0
NTERA-2-R/
NTERA-2
(41)
2102EP-R/
2102EP
(7)
31
2 3
2
NCCIT-R/
NCCIT
(33)
down-regulated up-/down-regulated
Figure 1 Venn diagram on total number (in parenthesis) and overlapping number of differentially expressed genes calculated in cell
line pairs consisting of the cisplatin-resistant (-R added to the paternal cell line’s name) relative to the cisplatin-sensitive paternal cell
line.
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Page 6 of 8resistance [2]. The tumor suppressor p21, regulating
transition through the cell cycle and acting downstream
of p53, has already been associated with hsa-miR520
belonging to the miR-106/302 family [14]. An increased
expression of miR-106/302 family members inhibits the
tumor suppressor p21 and rescues human mammary
epithelial cells from Ras-induced senescence [14]. In our
analysis, hsa-miR520c as well as hsa-miR520h were up-
regulated (3.9-7.1-fold) in NTERA-2-R/NTERA-2 and
NCCIT-R/NCCIT cell line pairs, which could point
towards another mechanism counteracting senescence.
In an in vitro model of cisplatin resistance of a squa-
mous cell carcinoma cell line, has-miR-21 was found to
be down-regulated in cisplatin resistant cells [15]. In our
cell line pairs, significant down-regulation of has-miR-21
was observed in NCCIT-R compared to sensitive
NCCIT cells. Furthermore, hsa-miR-146a, a microRNA
targeting BRCA1, was the most highly up-regulated
microRNA in another in vitro model of cisplatin resis-
tance of the breast cancer cell line MCF7 [16]. Similarly,
both NTERA-2-R/NTERA-2 and NCCIT-R/NCCIT
showed up-regulation in our analysis, yet to a lesser
e x t e n t .H o w e v e r ,h a s - m i R - 2 2 1 ,w h i c hw a sa l s oh i g h l y
up-regulated in cisplatin resistant MCF7 cells, was
down-regulated in NCCIT-R and unaltered in the other
two cell lines in our experiments, indicating that cispla-
tin resistance seems to be cell line or tumor type speci-
fic. In a lymphoblastic leucemia cell line overexpression
of hsa-miR-125b conferred a survival advantage through
inhibition of caspase 3 activation after exposure to a
broad spectrum of apoptotic stimuli [17]. In our analy-
sis, however, hsa-miR-125b appeared to be up to 5-fold
down-regulated in NCCIT-R/NCCIT and 2102EP-R/
2102EP cell line pairs, thus making an inhibition of
apoptosis through this micro-RNA species unlikely.
According to our analysis, further micro-RNA species
appeared either about 8-fold up-regulated (hsa-miR-512-
3p/-515/-517/-518/-525) or about 10-fold down-regulated
(hsa-miR-99a/-100/-145) in both NTERA-2-R/NTERA-2
and NCCIT-R/NCCIT cell line pairs. Literature results
describing a role of these micro-RNAs in cisplatin resis-
tance are missing, warranting further studies to elucidate
their potential role in development of resistance.
Recently, a role of the miR-106b seed family members
in cisplatin resistance of testicular cancer has been
described by another group [18]. Although detectable,
neither miRNA-106b, nor miRNA-106a, miRNA-17-5,
miRNA-93, and miRNA-20 were differentially expressed
in our model. In our view, this points at the multifactor-
ial nature of cisplatin resistance in germ cell tumors.
Conclusions
In summary, our approach, simultaneously examining
almost all known human micro-RNA species, confirms
that the miR-371-373 cluster seems to be involved in
c i s p l a t i nr e s i s t a n c ei ng e r mc e l lt u m o r si nv i t r oa n d
could be an interesting target for interference with drug
resistance. Moreover, new micro-RNA species such as
hsa-miR-512-3p/-515/-517/-518/-525 or hsa-miR-99a/-
100/-145, also potentially involved in cisplatin resistance,
could be identified in the germ cell tumor cell lines stu-
died here. It will be of interest to examine tumor sam-
ples of patients with both cisplatin-sensitive and
cisplatin-resistant germ cell tumors to analyse whether
the changes described here are also found in vivo.
Furthermore, functional analyses, e.g. by employing si-
RNA and simultaneous whole genome microarrays, can
help to examine the causal link with cisplatin resistance
and to get insight into the mRNA species controlled by
the micro-RNAs.
Additional material
Additional file 1: Table S1: Complete list of all detectable miRNA
examined. Differential gene expression relative to the corresponding
gene of the paternal cell line - complete list of all detectable miRNAs
examined (lying within the linear-dynamic range of our method)
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